Related references
Note: Only part of the references are listed.Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy
Asmita Pal et al.
FRONTIERS IN MICROBIOLOGY (2020)
Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice
Amit S. Choudhari et al.
FRONTIERS IN PHARMACOLOGY (2020)
Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis
Catherine de Martel et al.
LANCET GLOBAL HEALTH (2020)
Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis
Marc Arbyn et al.
LANCET GLOBAL HEALTH (2020)
N-(2′-Hydroxyphenyl)-2-Propylpentanamide (HO-AAVPA) Inhibits HDAC1 and Increases the Translocation of HMGB1 Levels in Human Cervical Cancer Cells
Yudibeth Sixto-Lopez et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Hallmarks of HPV carcinogenesis: The role of E6, E7 and E5 oncoproteins in cellular malignancy
Diogo Estevao et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2019)
Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview
Suvankar Banerjee et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Quantitative Chemotherapeutic Profiling of Gynecologic Cancer Cell Lines using Approved Drugs and Bioactive Compounds
Kirill Gorshkov et al.
TRANSLATIONAL ONCOLOGY (2019)
Quercetin modifies 5′CpG promoter methylation and reactivates various tumor suppressor genes by modulating epigenetic marks in human cervical cancer cells
Madhumitha Kedhari Sundaram et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
Factors associated with high-risk human papillomavirus infection and high-grade cervical neoplasia: A population-based study in Paraguay
Elena Kasamatsu et al.
PLOS ONE (2019)
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
J. Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
撤稿声明: Molecular mechanisms in progression of HPV-associated cervical carcinogenesis (Retraction of Vol 26, Pg 28, 2019)
Sadhana M. Gupta et al.
JOURNAL OF BIOMEDICAL SCIENCE (2019)
EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma
Kyriaki Tzogani et al.
ONCOLOGIST (2018)
Synergistic anticancer effect of panobinostat and topoisomerase inhibitors through ROS generation and intrinsic apoptotic pathway induction in cervical cancer cells
Lubna Wasim et al.
CELLULAR ONCOLOGY (2018)
The natural history of human papillomavirus infection
Silvia de Sanjose et al.
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY (2018)
Overexpressed HDAC8 in cervical cancer cells shows functional redundancy of tubulin deacetylation with HDAC6
G. R. Vanaja et al.
CELL COMMUNICATION AND SIGNALING (2018)
Designing Isoform-selective Inhibitors Against Classical HDACs for Effective Anticancer Therapy: Insight and Perspectives from In Silico
Shabir Ahmad Ganai
CURRENT DRUG TARGETS (2018)
Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors
Jooeun Bae et al.
LEUKEMIA (2018)
The HPV E6/E7 Oncogenes: Key Factors for Viral Carcinogenesis and Therapeutic Targets
Karin Hoppe-Seyler et al.
TRENDS IN MICROBIOLOGY (2018)
Resveratrol and Pterostilbene Exhibit Anticancer Properties Involving the Downregulation of HPV Oncoprotein E6 in Cervical Cancer Cells
Kaushiki Chatterjee et al.
NUTRIENTS (2018)
HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors
Rekha Sangwan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
N-(2´-Hydroxyphenyl)-2-propylpentanamide (OH-VPA), a histone deacetylase inhibitor, induces the release of nuclear HMGB1 and modifies ROS levels in HeLa cells
Arturo Contis-Montes de Oca et al.
Oncotarget (2018)
Beyond histone acetylation-writing and erasing histone acylations
Shuai Zhao et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2018)
Vorinostat, a pan-HDAC inhibitor, abrogates productive HPV-18 DNA amplification
N. Sanjib Banerjee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Tobacco Exposure Enhances Human Papillomavirus 16 Oncogene Expression via EGFR/PI3K/Akt/c-Jun Signaling Pathway in Cervical Cancer Cells
Juan P. Munoz et al.
FRONTIERS IN MICROBIOLOGY (2018)
Evaluation of Novel 3-Hydroxyflavone Analogues as HDAC Inhibitors against Colorectal Cancer
Subhankar Biswas et al.
ADVANCES IN PHARMACOLOGICAL SCIENCES (2018)
Targeting triple negative breast cancer with histone deacetylase inhibitors
Palma Fedele et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Antitumor platinum(IV) derivatives of carboplatin and the histone deacetylase inhibitor 4-phenylbutyric acid
Awatif Rashed Z. Almotairy et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2017)
The Essential Medicinal Chemistry of Curcumin
Kathryn M. Nelson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Epigenetic Alterations in Human Papillomavirus-Associated Cancers
David Soto et al.
VIRUSES-BASEL (2017)
Unique synergistic formulation of curcumin, epicatechin gallate and resveratrol, tricurin, suppresses HPV E6, eliminates HPV plus cancer cells, and inhibits tumor progression
Sumit Mukherjee et al.
ONCOTARGET (2017)
The role of integration in oncogenic progression of HPV-associated cancers
Alison A. McBride et al.
PLOS PATHOGENS (2017)
Induction of colon and cervical cancer cell death by cinnamic acid derivatives is mediated through the inhibition of Histone Deacetylases (HDAC)
Preethi G. Anantharaju et al.
PLOS ONE (2017)
A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma
Andrew M. Evens et al.
CLINICAL CANCER RESEARCH (2016)
Panobinostat induces apoptosis via production of reactive oxygen species and synergizes with topoisomerase inhibitors in cervical cancer cells
Lubna Wasim et al.
BIOMEDICINE & PHARMACOTHERAPY (2016)
PXD101 analogs with L-phenylglycine-containing branched cap as histone deacetylase inhibitors
Jingyao Li et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2016)
Clinical significance of human papillomavirus genotyping
Youn Jin Choi et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2016)
Natural Products as Sources of New Drugs from 1981 to 2014
David J. Newman et al.
JOURNAL OF NATURAL PRODUCTS (2016)
Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53
Denise Martinez-Zapien et al.
NATURE (2016)
HPV 16E7 and 48E7 proteins use different mechanisms to target p130 to overcome cell cycle block
Nurshamimi Nor Rashid et al.
VIROLOGY JOURNAL (2016)
Development of a Potent and Selective HDAC8 Inhibitor
Oscar J. Ingham et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Unraveling the Anticancer Effect of Curcumin and Resveratrol
Aline Renata Pavan et al.
NUTRIENTS (2016)
Extrachromosomal HPV-16 LCR transcriptional activation by HDACi opposed by cellular differentiation and DNA integration
Ekaterina Dimitrova Bojilova et al.
ONCOTARGET (2016)
Prevalence, Genotype Distribution and Risk Factors for Cervical Human Papillomavirus Infection in the Grand Tunis Region, Tunisia
Monia Ardhaoui et al.
PLOS ONE (2016)
Identification of Histone Deacetylase Inhibitors with Benzoylhydrazide Scaffold that Selectively Inhibit Class I Histone Deacetylases
Yunfei Wang et al.
CHEMISTRY & BIOLOGY (2015)
Luotonin-A based quinazolinones cause apoptosis and senescence via HDAC inhibition and activation of tumor suppressor proteins in HeLa cells
Ramineni Venkatesh et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
The Acetyltransferase Tip60 Is a Critical Regulator of the Differentiation-Dependent Amplification of Human Papillomaviruses
Shiyuan Hong et al.
JOURNAL OF VIROLOGY (2015)
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
Madhusoodanan Mottamal et al.
MOLECULES (2015)
HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Cristabelle Souza et al.
Recent Patents on Anti-Cancer Drug Discovery (2015)
Acetylation of intragenic histones on HPV16 correlates with enhanced HPV16 gene expression
Cecilia Johansson et al.
VIROLOGY (2015)
Human Papillomaviruses; Epithelial Tropisms, and the Development of Neoplasia
Nagayasu Egawa et al.
VIRUSES-BASEL (2015)
The Deacetylase Sirtuin 1 Regulates Human Papillomavirus Replication by Modulating Histone Acetylation and Recruitment of DNA Damage Factors NBS1 and Rad51 to Viral Genomes
Erika S. Langsfeld et al.
PLOS PATHOGENS (2015)
A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma
Francine Foss et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Synergistic enhancement of anticancer effects on numerous human cancer cell lines treated with the combination of EGCG, other green tea catechins, and anticancer compounds
Hirota Fujiki et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2015)
Role of human papillomaviruses in carcinogenesis
Raffaella Ghittoni et al.
ECANCERMEDICALSCIENCE (2015)
Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8+ T cell immune response and antitumor effects in a preclinical cervical cancer model
Zhuomin Huang et al.
JOURNAL OF BIOMEDICAL SCIENCE (2015)
Human Viral Oncogenesis: A Cancer Hallmarks Analysis
Enrique A. Mesri et al.
CELL HOST & MICROBE (2014)
Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer
Alfonso Duenas-Gonzalez et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2014)
SAHA inhibits the transcription initiation of HPV18 E6/E7 genes in HeLa cervical cancer cells
Hongpeng He et al.
GENE (2014)
Suberoylanilide hydroxamic acid-induced HeLa cell death is closely correlated with oxidative stress and thioredoxin 1 levels
Bo Ra You et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Curcumin Augments the Efficacy of Antitumor Drugs Used in Leukemia by Modulation of Heat Shock Proteins Via HDAC6
Ruma Sarkar et al.
JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY (2014)
Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways
Sarah R. Hosford et al.
PHARMACOGENOMICS & PERSONALIZED MEDICINE (2014)
Transactivation of bad by vorinostat-induced acetylated p53 enhances doxorubicin-induced cytotoxicity in cervical cancer cells
Sook-Jeong Lee et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2014)
Structural basis for the design and synthesis of selective HDAC inhibitors
Simone Di Micco et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2013)
Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability
Benjamin E. L. Lauffer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Histone Deacetylase (HDAC) 10 Suppresses Cervical Cancer Metastasis through Inhibition of Matrix Metalloproteinase (MMP) 2 and 9 Expression
Chenlin Song et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Crebinostat: A novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity
Daniel M. Fass et al.
NEUROPHARMACOLOGY (2013)
Valproic acid inhibits the growth of HeLa cervical cancer cells via caspase-dependent apoptosis
Bo Ram Han et al.
ONCOLOGY REPORTS (2013)
Targeting of Histone Deacetylases to Reactivate Tumour Suppressor Genes and Its Therapeutic Potential in a Human Cervical Cancer Xenograft Model
Dingqing Feng et al.
PLOS ONE (2013)
Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells
Jee-Eun Kim et al.
PHARMACOLOGICAL RESEARCH (2013)
Structural Basis for Hijacking of Cellular LxxLL Motifs by Papillomavirus E6 Oncoproteins
Katia Zanier et al.
SCIENCE (2013)
Enhanced cytotoxic effects of combined valproic acid and the Aurora kinase inhibitor VE465 on gynecologic cancer cells
Yanfang Li et al.
FRONTIERS IN ONCOLOGY (2013)
Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases
Vijay S. Thakur et al.
CARCINOGENESIS (2012)
Dimethylcelecoxib induces an inhibitory complex consisting of HDAC1/NF-κB(p65) RelA leading to transcriptional downregulation of mPGES-1 and EGR1
Klaus Deckmann et al.
CELLULAR SIGNALLING (2012)
Epithelial Cell Responses to Infection with Human Papillomavirus
Margaret A. Stanley
CLINICAL MICROBIOLOGY REVIEWS (2012)
Combination of Valproic Acid and ATRA Restores RARβ2 Expression and Induces Differentiation in Cervical Cancer through the PI3K/Akt Pathway
D. Feng et al.
CURRENT MOLECULAR MEDICINE (2012)
Immune Mechanism of the Antitumor Effects Generated by Bortezomib
Chih-Long Chang et al.
JOURNAL OF IMMUNOLOGY (2012)
A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer
Michael Herfs et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
The Biology and Life-Cycle of Human Papillomaviruses
John Doorbar et al.
VACCINE (2012)
Cancer associated human papillomaviruses
Margaret E. McLaughlin-Drubin et al.
CURRENT OPINION IN VIROLOGY (2012)
In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC)
Usman S. F. Tambunan et al.
BMC BIOINFORMATICS (2011)
Inhibitors of Histone Deacetylases CORRELATION BETWEEN ISOFORM SPECIFICITY AND REACTIVATION OF HIV TYPE 1 (HIV- 1) FROM LATENTLY INFECTED CELLS
Kelly Huber et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Human Papillomavirus Infection with Multiple Types: Pattern of Coinfection and Risk of Cervical Disease
Anil K. Chaturvedi et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results
Jaime Coronel et al.
MEDICAL ONCOLOGY (2011)
Apicidin upregulates PHD2 prolyl hydroxylase gene expression in cervical cancer cells
Marta Durczak et al.
ANTI-CANCER DRUGS (2010)
Dimethylcelecoxib inhibits mPGES-1 promoter activity by influencing EGR1 and NF-κB
Klaus Deckmann et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors
Patrick Angibaud et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Identification of a better Homo sapiens Class II HDAC inhibitor through binding energy calculations and descriptor analysis
Usman Sumo Friend Tambunan et al.
BMC BIOINFORMATICS (2010)
The effect of combined treatment with cisplatin and histone deacetylase inhibitors on HeLa cells
Ke Long Jin et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2010)
Synergistic induction of apoptosis in HeLa cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitor SAHA
Yizhou Jiang et al.
MOLECULAR MEDICINE REPORTS (2010)
Host Factors in HPV-related Carcinogenesis: Cellular Mechanisms Controlling HPV Infections
Magnus von Knebel Doeberitz et al.
ARCHIVES OF MEDICAL RESEARCH (2009)
Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies
Gamze Bora-Tatar et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2009)
Combination of Proteasome and HDAC Inhibitors for Uterine Cervical Cancer Treatment
Zhenhua Lin et al.
CLINICAL CANCER RESEARCH (2009)
Prevalence of HPV infection by cervical cytologic status in Brazil
Jose Verissimo Fernandes et al.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS (2009)
A review of human carcinogens-Part B: biological agents
Veronique Bouvard et al.
LANCET ONCOLOGY (2009)
Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline
Mark Schiffman et al.
Infectious Agents and Cancer (2009)
High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas
Mehdi Ouaissi et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
Nagma Khan et al.
BIOCHEMICAL JOURNAL (2008)
Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?
L. Nolan et al.
BRITISH JOURNAL OF CANCER (2008)
Apicidin down-regulates human papillomavirus type 16 E6 and E7 transcripts and proteins in SiHa cervical cancer cells
Michal W. Luczak et al.
CANCER LETTERS (2008)
Co-Expression of HSV2 and Chlamydia trachomatis in HPV-Positive Cervical Cancer and Cervical Intraepithelial Neoplasia Lesions Is Associated with Aberrations in Key Intracellular Pathways
Pierpaolo Paba et al.
INTERVIROLOGY (2008)
Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo
Siraj Sami et al.
JOURNAL OF BIOCHEMISTRY (2008)
Proteomic analysis of cervical cancer cells treated with suberonylanilide hydroxamic acid
Jianxiong He et al.
JOURNAL OF BIOSCIENCES (2008)
Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells
Marielle Dejligbjerg et al.
MOLECULAR CANCER (2008)
Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function
Shashwati Basak et al.
MOLECULAR CANCER THERAPEUTICS (2008)
A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas
S. Balasubramanian et al.
LEUKEMIA (2008)
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men
Xiang-Jiao Yang et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Radiosensitization by the histone deacetylase inhibitor PCI-24781
Carmen A. Banuelos et al.
CLINICAL CANCER RESEARCH (2007)
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors:: A clinical and translational study
Pamela Muenster et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors
Diana C. Birle et al.
CANCER RESEARCH (2007)
Human endometrial and ovarian cancer cells: Histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis
Noriyuki Takai et al.
CURRENT MEDICINAL CHEMISTRY (2007)
CRA-024781:: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo
Joseph J. Buggy et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling
MJ Evans et al.
NATURE BIOTECHNOLOGY (2005)
Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study
Alma Chavez-Blanco et al.
MOLECULAR CANCER (2005)
Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1
BH Huang et al.
CELL DEATH AND DIFFERENTIATION (2005)
Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis
IV Gregoretti et al.
JOURNAL OF MOLECULAR BIOLOGY (2004)
Histone deacetylase is a target of valproic acid-mediated cellular differentiation
N Gurvich et al.
CANCER RESEARCH (2004)
Induction of histone acetylation and inhibition of growth by phenyl alkanoic acids and structurally related molecules
MA Lea et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
HDAC6 is a microtubule-associated deacetylase
C Hubbert et al.
NATURE (2002)
Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer
RW Johnstone
NATURE REVIEWS DRUG DISCOVERY (2002)
Expression profile of histone deacetylase 1 in gastric cancer tissues
JH Choi et al.
JAPANESE JOURNAL OF CANCER RESEARCH (2001)
Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7
SL Gonzalez et al.
JOURNAL OF VIROLOGY (2001)